Press release
Fabry Disease Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight
Fabry Disease Pipeline
"Fabry Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Fabry Disease Market.
The Fabry Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Fabry Disease Pipeline Report:
• Fabry Disease Companies across the globe are diligently working toward developing novel Fabry Disease treatment therapies with a considerable amount of success over the years.
• Fabry Disease companies working in the treatment market are Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, AVROBIO, Freeline Therapeutics, Ozmosis Research Inc., CellGenTech, Inc., uniQure, Codexis, Canbridge, Eleva GmbH, MP6 Therapeutics, Amicus Therapeutics, Sigilon Therapeutics, and others are developing therapies for the Fabry Disease treatment
• Emerging Fabry Disease therapies such as Venglustat, Pegunigalsidase alfa, 4D 310, and others are expected to have a significant impact on the Fabry Disease market in the coming years.
• In July 2024, Sanofi announced a Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion
• Sangamo Therapeutics, Inc.: ST-920 (Isaralgagene Civaparvovec): Sangamo announced alignment with the FDA on an accelerated approval pathway for ST-920 in October 2024. The Phase 1/2 STAAR study is ongoing, and the company expects to submit a Biologics License Application (BLA) in the second half of 2025.
• uniQure: AMT-191: Patient enrollment in the clinical trial for AMT-191, a gene therapy candidate for Fabry Disease, began in the first half of 2024. The Phase 1/2 trial is evaluating the safety and efficacy of this investigational therapy.
Fabry Disease Overview
Fabry Disease is a rare genetic disorder that prevents the body from making an enzyme called alpha-galactosidase A. This enzyme is responsible for breaking down a type of fat called globotriaosylceramide (Gb3 or GL-3) into building blocks that the body's cells can use. Fabry Disease can have many symptoms because it affects cells throughout the body. The symptoms include: Chronic pain - usually a burning or tingling sensation - in the hands and feet, Clusters of small, dark red spots in various locations on the skin, Opaque corneas, resulting in cloudy-looking eyes and problems with eyesight, Ringing in the ears, and hearing loss. Fabry Disease is caused by a mutation of the GLA gene, which encodes for the alpha-galactosidase A enzyme. The mutation usually makes the enzyme unable to function, although in mild cases, it may function to some degree. The disease is inherited in an X-linked dominant manner, which means that the gene involved is situated on the X chromosome.
Get a Free Sample PDF Report to know more about Fabry Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Fabry Disease Route of Administration
Fabry Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
Fabry Disease Molecule Type
Fabry Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Fabry Disease Pipeline Therapeutics Assessment
• Fabry Disease Assessment by Product Type
• Fabry Disease By Stage and Product Type
• Fabry Disease Assessment by Route of Administration
• Fabry Disease By Stage and Route of Administration
• Fabry Disease Assessment by Molecule Type
• Fabry Disease by Stage and Molecule Type
DelveInsight's Fabry Disease Report covers around 18+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Fabry Disease product details are provided in the report. Download the Fabry Disease pipeline report to learn more about the emerging Fabry Disease therapies @ https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Fabry Disease Pipeline Analysis:
The Fabry Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Fabry Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fabry Disease Treatment.
• Fabry Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Fabry Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fabry Disease market.
Download Sample PDF Report to know more about Fabry Disease drugs and therapies- https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Fabry Disease Pipeline Drug Insight
• Coverage: Global
• Key Fabry Disease Companies: Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, AVROBIO, Freeline Therapeutics, Ozmosis Research Inc., CellGenTech, Inc., uniQure, Codexis, Canbridge, Eleva GmbH, MP6 Therapeutics, Amicus Therapeutics, Sigilon Therapeutics, and others.
• Key Fabry Disease Therapies: Venglustat, Pegunigalsidase alfa, 4D 310, and others.
• Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies
• Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers
Request for Sample PDF Report for Fabry Disease Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Fabry Disease Report Introduction
2. Fabry Disease Executive Summary
3. Fabry Disease Overview
4. Fabry Disease- Analytical Perspective In-depth Commercial Assessment
5. Fabry Disease Pipeline Therapeutics
6. Fabry Disease Late Stage Products (Phase II/III)
7. Fabry Disease Mid Stage Products (Phase II)
8. Fabry Disease Early Stage Products (Phase I)
9. Fabry Disease Preclinical Stage Products
10. Fabry Disease Therapeutics Assessment
11. Fabry Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Fabry Disease Companies
14. Fabry Disease Key Products
15. Fabry Disease Unmet Needs
16 . Fabry Disease Market Drivers and Barriers
17. Fabry Disease Future Perspectives and Conclusion
18. Fabry Disease Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/r-and-d-analysis
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage-gastrointestinal-cancers
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight here
News-ID: 3826214 • Views: …
More Releases from DelveInsight Business Research
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape.
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the…
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
More Releases for Fabry
Key Factor Supporting Global Fabry Disease Treatment Market Development in 2025: …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Fabry Disease Treatment Market Size By 2025?
The valuation of the Fabry disease treatment market has experienced robust expansion recently, projected to advance from $2.09 billion in 2024 up to $2.27 billion by 2025, reflecting an 8.8% compound annual growth rate during this timeframe. This…
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
